Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Suliqua

Suliqua 100 units/ml + 50 micrograms/ml solution for injection in pre-filled pen Suliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 11

HOS-136799 · Präparat HOS-097920

Table 2: Documented symptomatic or severe hypoglycaemic adverse reactions Insulin naïve patients Switch from Switch from GLP-1 basal insulin receptor agonist*** Suliqua Insulin Lixisenatide Suliqua Insulin Suliqua GLP-1 glargine glargine receptor agonist*** N 469 467 233 365 365 255 256 Documented symptomatic hypoglycaemia* Patients with event, 120 110 15 146 155 71 6 n (%) (25.6%) (23.6%) (6.4%) (40.0%) (42.5%) (27.8%) (2.3%) Events per patient- 1.44 1.22 0.34 3.03 4.22 1.54 0.08 year, n Severe hypoglycaemia** Events per patient- year, 0 <0.01 0 0.02 <0.01 <0.01 0 n * Documented symptomatic hypoglycaemia was an event during which typical symptoms of hypoglycaemia were accompanied by a measured plasma glucose concentration of ≤3.9 mmol/L. ** Severe symptomatic hypoglycaemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. *** Liraglutide, exenatide BID (twice in a day) or extended release, dulaglutide or albiglutide

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.